Evidence map›Paper›PMID 26275779›Full record

Trial reportAnnals of surgical oncology2015

Comparison of Post-injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy.

Jonathan T Unkart, Jennifer L Baker, Ava Hosseini, Carl K Hoh, Mark S Wallace, David R Vera, Anne M Wallace

Open access · hybridAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. European journal of nuclear medicine and molecular imaging · 2023
    Pooled it
  2. Trial
  3. Review
  4. Cost-Effectiveness of [Annals of surgical oncology · 2023
    Article
  5. Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma.Current treatment options in oncology · 2021
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jonathan T UnkartDepartment of Surgery, University of California, San Diego, La Jolla, CA, 92093, USA.
Jennifer L BakerDepartment of Surgery, University of California, San Diego, La Jolla, CA, 92093, USA.
Ava HosseiniDepartment of Surgery, University of California, San Diego, La Jolla, CA, 92093, USA.
Carl K HohDepartment of Radiology, University of California, San Diego, La Jolla, CA, USA.
Mark S WallaceDepartment of Anesthesia, University of California, San Diego, La Jolla, CA, USA.
David R VeraDepartment of Radiology, University of California, San Diego, La Jolla, CA, USA.
Anne M WallaceDepartment of Surgery, University of California, San Diego, La Jolla, CA, 92093, USA. amwallace@ucsd.edu.
University of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNo prior studies have examined injection pain associated with Technetium-99m Tilmanocept (TcTM).

methodsThis was a randomized, double-blinded study comparing postinjection site pain between filtered Technetium Sulfur Colloid (fTcSC) and TcTM in breast cancer lymphoscintigraphy. Pain was evaluated with a visual analogue scale (VAS) (0-100 mm) and the short-form McGill Pain Questionnaire (SF-MPQ). The primary endpoint was mean difference in VAS scores at 1-min postinjection between fTcSC and TcTM. Secondary endpoints included a comparison of SF-MPQ scores between the groups at 5 min postinjection and construction of a linear mixed effects model to evaluate the changes in pain during the 5-min postinjection period.

resultsFifty-two patients underwent injection (27-fTcSC, 25-TcTM). At 1-min postinjection, patients who received fTcSC experienced a mean change in pain of 16.8 mm (standard deviation (SD) 19.5) compared with 0.2 mm (SD 7.3) in TcTM (p = 0.0002). At 5 min postinjection, the mean total score on the SF-MPQ was 2.8 (SD 3.0) for fTcSC versus 2.1 (SD 2.5) for TcTM (p = 0.36). In the mixed effects model, injection agent (p < 0.001), time (p < 0.001) and their interaction (p < 0.001) were associated with change in pain during the 5-min postinjection period. The model found fTcSC resulted in significantly more pain of 15.2 mm (p < 0.001), 11.3 mm (p = 0.001), and 7.5 mm (p = 0.013) at 1, 2, and 3 min postinjection, respectively.

conclusionsInjection with fTcSC causes significantly more pain during the first 3 min postinjection compared with TcTM in women undergoing lymphoscintigraphy for breast cancer.

Indexed as

Breast NeoplasmsDextransDouble-Blind MethodFemaleFollow-Up StudiesHumansLymph NodesLymphoscintigraphyMannansMiddle AgedNeoplasm StagingPainPrognosisRadiopharmaceuticalsSentinel Lymph Node BiopsyTechnetium Tc 99m PentetateDextransMannansRadiopharmaceuticalstechnetium-diethylenetriaminepentaacetic acid-mannosyl-dextranTechnetium Tc 99m PentetateTechnetium Tc 99m Sulfur Colloid

Identifiers

PMID26275779
PMCPMC4686557
OpenAlexW1145411314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.